XML 64 R54.htm IDEA: XBRL DOCUMENT v3.25.3

Option Agreements and License Agreements (Details) - USD ($) $ in Millions	3 Months Ended		8 Months Ended	9 Months Ended	11 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2025	Dec. 31, 2024
Option Agreements and License Agreements [Line Items]
Expenses	$ 9.6	$ 13.4	$ 33.8	$ 15.3
Paruka Warrant Obligation [Member]
Option Agreements and License Agreements [Line Items]
Warrant purchase percentage					1.00%
ORKA-002 [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments				4.0
Milestone consideration paid	3.0			3.0
Research and development expenses		3.8	10.7	0.1
Milestone payment				2.5
ORKA-001 [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments				$ 7.0
Development costs				50.00%
Research and development expenses		$ 0.8	$ 14.0
Related Party [Member] | ORKA-002 [Member]
Option Agreements and License Agreements [Line Items]
Accounts payable and other current liabilities					$ 2.7
Related Party [Member] | ORKA-001 [Member]
Option Agreements and License Agreements [Line Items]
Accounts payable and other current liabilities					12.4
Paragon [Member] | ORKA-002 [Member] | Research and Development Expense [Member] | Exercising Option [Member]
Option Agreements and License Agreements [Line Items]
Nonrefundable research initiation fee					0.8
Paragon [Member] | ORKA-002 [Member] | Research and Development Expense [Member] | Achievement of Development Candidate [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid					$ 1.5
Paragon [Member] | Option Agreement [Member] | Antibody Products [Member]
Option Agreements and License Agreements [Line Items]
Royalty payable on product sales, description					low single-digit percentage royalty for antibody products
Paragon [Member] | ORKA-001 [Member] | Research and Development Expense [Member] | Exercising Option [Member]
Option Agreements and License Agreements [Line Items]
Nonrefundable research initiation fee					$ 0.8
Paragon [Member] | ORKA-001 [Member] | Research and Development Expense [Member] | Achievement of Development Candidate [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid					1.5
Paragon [Member] | ORKA-001 [Member] | Research and Development Expense [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid					2.5
Maximum [Member] | Paragon [Member] | Clinical Development Milestones [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments					12.0
Maximum [Member] | Paragon [Member] | Regulatory Milestones Member [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments					10.0
Maximum [Member] | Paragon [Member] | ORKA-002 [Member] | Clinical Development Milestones [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments					$ 12.0

X

- Definition

class of warrant or right to purchase percentage of outstanding diluted stock maximum.

+ References

No definition available.

+ Details

Name:	orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
Namespace Prefix:	orka_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Development cost.

+ References

No definition available.

+ Details

Name:	orka_DevelopmentCost
Namespace Prefix:	orka_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of milestone consideration paid.

+ References

No definition available.

+ Details

Name:	orka_MilestoneConsiderationPaid
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of milestone payment.

+ References

No definition available.

+ Details

Name:	orka_MilestonePayment
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non refundable initiation fee.

+ References

No definition available.

+ Details

Name:	orka_NonRefundableInitiationFee
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non-refundable milestone payments.

+ References

No definition available.

+ Details

Name:	orka_NonRefundableMilestonePayments
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Royalty payable on product sales, description.

+ References

No definition available.

+ Details

Name:	orka_RoyaltyPayableOnProductSales
Namespace Prefix:	orka_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableOtherCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=orka_ParagonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ExercisingOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_OptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: